Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: Assessment of acute urinary retention and prostate-related surgery

Current Medical Research and Opinion

Volumn 25, Issue 11, 2009, Pages 2663-2669

  Naslund, Michael ^a   Eaddy, Michael T ^b   Hogue, Susan L ^c   Kruep, Eric J ^b   Shah, Manan B ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b XCENDA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

5 alpha reductase inhibitor; Acute urinary retention; Alpha blocker; Benign prostatic hyperplasia; Enlarged prostate; Prostate surgery

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ACUTE DISEASE; ADD ON THERAPY; ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; THERAPY DELAY; TREATMENT OUTCOME; URINE RETENTION;

ACUTE DISEASE; ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; TESTOSTERONE 5-ALPHA-REDUCTASE; TIME FACTORS; URINARY RETENTION;

EID: 72549102776     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903210330     Document Type: Article

References (15)

1. Issa MM, Fenter TC, Black L, et al. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 2006;12(4 Suppl):S83-9
2. Naslund MJ, Issa MM, Grogg AL, et al. Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care 2006;12(4 Suppl):S111-6
3. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-563 (Pubitemid 28114643)
4. US Census Bureau. US interim projections by age, sex, race, and Hispanic origin. Available at: http://www.census.gov/ipc/www/usinterimproj/. Accessed November 2007
5. Kaplan SA. Update on the American Urological Association guidelines for the treatment of benign prostatic hyperplasia. Rev Urol 2006;8(Suppl 4):S10-17
6. Barkin J, Guimarães M, Jacobi G, et al. Alpha blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha reductase inhibitor dutasteride. Eur Urol 2003;44:461-466 (Pubitemid 37185673)
7. AUA Practice Guidelines Committee, authors. AUA guideline on management of benign prostatic hyperplasia (2003), chapter 1: diagnosis and treatment recommendations. J Urol 2003;170(2 pt 1):530-547
8. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003;349:2387-2398
9. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999;54:670-678
10. Roehrborn CG, Boyle P, Nickel JC, et al., on behalf of the ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 4-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-441
11. Baldwin KC, Ginsberg PC, Roehrborn CG, et al. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001;58:203-209
12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
14. Roehrborn CG, Bruskewitz R, Nickel JC, et al., for the Proscar Long-term Efficacy and Safety Study Group. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 2004;171:1194-1198
15. Roehrborn C, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT Study. J Urol 2008;179:616-621